Chapter 19 The last straw that breaks Zhang Yang’s life!
“No subsidy?”
Ren Xiaomin looked stunned, a little confused.
But he reacted the next second.
“Zhang Yang, you don’t want us to continue on our own and continue to advance the next three clinical phases, right?”
Zhang Yang nodded solemnly, and then recounted the incident that happened to Li Bing and others in the hematology clinic a few days ago.
“In fact, I have also noticed in the past few days that compared with when we first recruited patients, the difficulty of recruiting patients has been greatly reduced in the past half month!”
“Especially in the last one Almost all of the people who participated in the group trials came here because of it.”
“They don’t care about the enrollment subsidy, they just want to try our ‘Avatrombopag’!”
"So!"
As he spoke, Zhang Yang's expression became serious:
"Since Ding Jian is deliberately causing harm behind his back, if stopping patient subsidies can help us persevere, then why don't we try to continue on our own and complete the third phase of clinical trials ourselves? ?”
A trace of excitement flashed in Ren Xiaomin’s eyes.
In the past few months, he has also been working hard for the second clinical phase of "Qingshan Avatrombopag Tablets", and he has long regarded this matter as his career just like Zhang Yang!
Who would be willing to sell their business if it were not forced by reality?
"Okay, I'll calculate it right away!"
Ren Xiaomin took out a piece of scratch paper and started calculating quickly.
The clinical trial costs of an innovative drug are roughly divided into three parts.
The first part is the research and development expenses incurred by the continuous adjustments, improvements, and revisions of new drugs during the second and third phases of clinical trials.
No innovative drug is achieved overnight. In the clinical cycle that lasts several years, pharmaceutical companies will repeatedly improve key factors such as innovative ingredients and dosage by obtaining clinical data, side effects, etc.
The more adjustments are made, the higher the cost; the greater the magnitude of the modification, the higher the cost will naturally be.
This part is also the most expensive part of clinical trial costs.
Of course.
For "Avatrobopa Tablets" which are already complete products, there is no such expenditure at all.
The second part is the patient's subsidy fee.
The subsidy cost for each new drug may range from a few hundred yuan to as much as 10,000, 20,000, or 30,000 yuan.
In addition to cash subsidies, major pharmaceutical companies will also provide various benefits such as "subsidy for hospitalization expenses", "subsidy for reduction of treatment costs", "free medication" and other benefits based on the actual situation.
In short, it is to attract more qualified subjects to join the group.
The second phase trial of "Qingshan Avatrombopag Tablets" also provided a good subsidy plan.
After each subject is successfully enrolled, not only will he be given a cash subsidy of 7,000 yuan, but he will also receive an additional travel subsidy of 500 yuan each time he comes to the hospital for re-examination.
After calculation, each patient received a subsidy of 13,000 yuan, and the total subsidy for 105 subjects was 1.4 million yuan.
This is only the cost for 105 people in the second phase. The third clinical phase will not only have more people, but also a longer period. The cost is tens of millions according to a rough calculation!
The third part is the patient’s examination fees and the hospital’s cooperation fees.
The examinations required during clinical trials of a new drug are not as simple as ordinary people going to the hospital to experience. Not only do they involve many examination items, some of them are expensive,
Moreover, the number of examinations It is also far beyond ordinary people’s imagination.
Take the Phase III clinical program designed by "Qingshan Avatrombopag" as an example. During the three-month clinical trial period, there were a total of 16 checkpoints, including 12 general examinations and 4 comprehensive examinations.
These costs are borne by the pharmaceutical companies!
In addition, there are the cooperation expenses and regular expenses of the hospital. After all, without the full support of various departments of the hospital, it is almost difficult to promote the clinical practice of new drugs.
At present, Zhang Yang has to bear this part of the cost!
After a while, Ren Xiaomin calculated the result!
"Zhang Yang, if we calculate based on the 600 people we applied for in the third clinical phase, the examination fee plus some miscellaneous expenses can be controlled between 8 million and 10 million." "Of course, this is the most ideal situation, and no accidents can occur."
“Yeah.”
Zhang Yang nodded, this data was pretty much what he expected.
But...
During the second phase of the clinical trial, I spent almost all my savings, and even mortgaged my house. Currently, I only have hundreds of thousands of available funds left.
Even if you get a bank loan and max out your credit cards, you will probably be able to get less than 2 million. Where can you find the holes for the remaining millions?
He frowned inadvertently, and Ren Xiaomin on the side obviously saw Zhang Yang's trouble.
After thinking for a moment, he said:
"Zhang Yang, if you really want to continue to advance the third phase of clinical trials, I have some savings, probably around 2 million."
"If there is still a big difference, I can mortgage the house and get another loan of 4 million, which adds up to 6 million."
"If you need it, this money You can use it first, and when the new medicine comes on the market, you can pay me back after making money."
Zhang Yang looked at Ren Xiaomin with some emotion.
To be honest, in the past few months of working with Ren Xiaomin, apart from being a little soft-hearted, Brother Ren really has nothing to say about his character and personality.
He was no longer polite and gently patted Ren Xiaomin on the shoulder:
"Brother Ren, I won't be polite to you anymore."
"But can you make the decision on the mortgage of the house? Why don't you discuss it with your sister-in-law?"
Ren Xiaomin suddenly got excited, Then he hurriedly patted his chest:
"Don't worry, the master has the final say in matters at home!"
"Haha."
Zhang Yang laughed.
......
Of course Zhang Yang is not really worried that this incident will cause family conflicts in Ren Xiaomin. Both he and Ren Xiaomin are very aware of the value of "Qingshan Avatropopa".
Once the Phase III trial is completed and launched, a mere 6 million will be nothing to mention.
After making up their mind, both of them felt a lot more relaxed. In the next few days, Zhang Yang became less anxious and began to be less anxious to contact pharmaceutical companies.
Similarly, other pharmaceutical companies are no longer in a hurry. In the past few days, everyone has learned the details of Zhang Yang from their own channels.
As rumored, the founder and boss of Qingshan Pharmaceutical, Zhang Yang, has even mortgaged his house and car. Obviously, funds are very tight, and it is absolutely impossible to continue to advance the third phase of clinical trials without external help.
There is no money to promote the third phase of clinical trials, which means that the "Avatrombopag" in his hand must be traded!
The pharmaceutical companies were completely relieved. In addition to continuing to communicate with Zhang Yang normally, almost everyone was waiting for Zhang Yang to take the initiative to speak.
Once Zhang Yang takes the initiative, it will be time to switch between offense and defense!
In this wonderful environment, a delicate balance was formed between the two parties. About three weeks later, Zhang Yang collected over 1 million, and with the 6 million borrowed by Ren Xiaomin, the funds in his hand reached 8 million.
The funds are in place and the second phase is over. Now we are waiting for the approval of the third phase clinical plan of "Qingshan Avatrombopag".
Two weeks later, the Phase III clinical program of "Qingshan Avatrombopag" was approved!
Zhang Yang also didn’t expect that the “Clinical Phase III Trial Plan” submitted to the review center would be approved so quickly. When he carefully read the approval document, he was shocked!
In the clinical phase III trial plan they submitted, the number of subjects was 600, but now!
The number of subjects was increased by the review center to 1,800!
In other words,
If you want to complete the Phase III clinical trial and get the marketing approval, you must provide clinical data on 1,800 people!
And most importantly!
He suddenly realized that all his plans were disrupted!
(End of this chapter)